Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

NCT04407247 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Colitis
Lung Non-Small Cell Carcinoma
Malignant Genitourinary System Neoplasm
Malignant Solid Neoplasm
Melanoma

Interventions

BIOLOGICAL: Infliximab
BIOLOGICAL: Vedolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]